Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Magi Euregio Scs currently faces 2 pending office actions in the Biotechnology & Pharmaceuticals sector. The portfolio is split between 2 distinct examiners and 2 distinct art units. STEPHEN THOMAS KAPUSHOC is the busiest examiner, holding 1 busiest examiner pending action. This ratio of examiners to art units and pending actions reflects a diverse but small-scale prosecution effort where each matter is being treated as a separate technical entity.
Because there are 2 distinct art units involved, the 2 pending office actions may be subject to different internal policies or examination speeds. The busiest examiner, STEPHEN THOMAS KAPUSHOC, handles 1 busiest examiner pending action, leaving the other action to a second examiner. With 2 distinct examiners in total, there is no overlap in the personnel reviewing these Biotechnology & Pharmaceuticals applications. Practitioners should be prepared to manage 2 separate prosecution tracks, as the 2 pending office actions are isolated from one another by both examiner and art unit assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516241 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | KAPUSHOC, STEPHEN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516241 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | KAPUSHOC, STEPHEN THOMAS | — |
| 17941310 | COMPOSITION FOR THE TREATMENT OF RADIO-INDUCED ORAL MUCOSITIS | DURYEE, ALEXANDER MARSH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18516241 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 17941310 | COMPOSITION FOR THE TREATMENT OF RADIO-INDUCED ORAL MUCOSITIS | DURYEE, ALEXANDER MARSH | 1657 | §103 | Final Rejection | — | Pending | Sep 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial